Chronic Kidney Disease Clinical Trial
Official title:
The Association of Serum Sclerostin Levels,Echocardiographic Parameters, Arteriovenous Fistula Thrombosis and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients
Sclerostin, the product of the SOST gene, located on chromosome 17, locus q11.2 in humans,
was originally believed to be a non-classical Bone morphogenetic protein (BMP)
antagonist.Sclerostin was recently identified as a component of parathyroid hormone (PTH)
signal transduction.
Chronic kidney disease (CKD) is associated with abnormalities in bone and mineral
metabolism.New advances in the pathogenesis of renal osteodystrophy (ROD) change the
perspective from which many of its features and treatment are viewed. Calcium, phosphate,
parathyroid hormone (PTH), and vitamin D have been shown to be important determinants of
survival associated with kidney diseases. Now ROD dependent and independent of these factors
is linked to survival more than just skeletal frailty.Furthermore, ROD is shown to be an
underappreciated factor in the level of the serum phosphorus in CKD. The discovery and the
elucidation of the mechanism of hyperphosphatemia as a cardiovascular risk in CKD change the
view of ROD.
Emerging current data suggests a promising role for serum measurements of sclerostin in
addition to iPTH in the diagnosis of high bone turnover in chronic kidney disease-5D
patients (dialysis patients).
Because of the close relationship between ROD and cardiovascular disease, the aim of this
study is to investigate the association between sclerostin, arteriovenous fistula
thrombosis, echocardiography and carpal tunnel syndrome in maintenance hemodialysis
patients.
Sclerostin, the product of the SOST gene, located on chromosome 17, locus q11.2 in humans,
was originally believed to be a non-classical Bone morphogenetic protein (BMP)
antagonist.More recently Sclerostin has been identified as binding to LRP5/6 receptors and
inhibiting the Wnt signalling pathway .Wnt activation under these circumstances is
antagonistic to bone formation. Although the underlying mechanisms are unclear, it is
believed that the antagonism of BMP-induced bone formation by sclerostin is mediated by Wnt
signalling, but not BMP signalling pathways.
Sclerostin is produced by the osteocyte and has catabolic effects on bone formation. This
protein, with a length of 113 residues, has a dssp secondary structure that is 28% beta
sheet (6 strands; 32 residues. Sclerostin has an inhibitory effect on the lifetime of the
osteoblast. Sclerostin production by osteocytes is inhibited by parathyroid hormone,
mechanical loading and cytokines including oncostatin M, cardiotrophin-1 and leukemia
inhibitory factor. Sclerostin production is increased by calcitonin. Thus, osteoblast
activity is self regulated by a negative feedback system.Sclerostin was recently identified
as a component of parathyroid hormone (PTH) signal transduction.
Chronic kidney disease (CKD) is associated with abnormalities in bone and mineral
metabolism.Renal osteodystrophy (ROD) is one of the three components of chronic kidney
disease-mineral and bone disorder (CKD-MBD. Patients with CKD may develop various types of
bone disease, spanning the spectrum of extreme situations such as severe osteitis fibrosa,
osteomalacia, mixed osteopathy, and adynamic bone disease. In addition, patients may have
osteoporosis, which increases the risk for fractures, both in advanced and in less severe
CKD stages (2- 4),which, in turn, result in excess mortality New advances in the
pathogenesis of renal osteodystrophy (ROD) change the perspective from which many of its
features and treatment are viewed. Calcium, phosphate, parathyroid hormone (PTH), and
vitamin D have been shown to be important determinants of survival associated with kidney
diseases. Now ROD dependent and independent of these factors is linked to survival more than
just skeletal frailty.Furthermore, ROD is shown to be an underappreciated factor in the
level of the serum phosphorus in CKD. The discovery and the elucidation of the mechanism of
hyperphosphatemia as a cardiovascular risk in CKD change the view of ROD. Emerging current
data suggests a promising role for serum measurements of sclerostin in addition to iPTH in
the diagnosis of high bone turnover in chronic kidney disease-5D patients (dialysis
patients).
The demonstration that the level of serum sclerostin,which is directly produced by
osteocytes, is a good predictor for bone formation in patients with CKD may be of clinical
interest.Because of the close relationship between ROD and cardiovascular disease, the aim
of this study is to investigate the association between sclerostin, arteriovenous fistula
thrombosis, echocardiography and carpal tunnel syndrome in maintenance hemodialysis
patients.
;
Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |